Evidence map›Paper›PMID 41454399›Full record

ArticleBMC pharmacology & toxicology2025

Zinc oxide resveratrol nanoparticles ameliorate levofloxacin-induced hepatotoxicity in rat model.

Naglaa F Zaki, Sahar H Orabi, Hend M Abdel-Bar, Reda M Korany, Laila A AlShuraym, Lamya Ahmed Alkeridis, Mohamed M Ahmed

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Naglaa F ZakiDepartment of Biochemistry and Chemistry of Nutrition, Faculty of Veterinary Medicine, University of Sadat City, Sadat City, 32897, Egypt.
Sahar H OrabiDepartment of Biochemistry and Chemistry of Nutrition, Faculty of Veterinary Medicine, University of Sadat City, Sadat City, 32897, Egypt. sahar.orabi@vet.usc.edu.eg.
Hend M Abdel-BarDepartment of Pharmaceutics, Faculty of Pharmacy, University of Sadat City, Sadat City, 32897, Egypt.
Reda M KoranyDepartment of Pathology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.
Laila A AlShuraymDepartment of Biology, College of Science, Princess Nourah Bint Abdulrahman University, P.O. Box 84428, Riyadh, 11671, Saudi Arabia.
Lamya Ahmed AlkeridisDepartment of Biology, College of Science, Princess Nourah Bint Abdulrahman University, P.O. Box 84428, Riyadh, 11671, Saudi Arabia.
Mohamed M AhmedDepartment of Biochemistry and Chemistry of Nutrition, Faculty of Veterinary Medicine, University of Sadat City, Sadat City, 32897, Egypt.

Funding

Princess Nourah bint Abdulrahman University Researchers Supporting Project PNURSP2025R365
6 · The paper itself

Abstract

backgroundThe present investigation assessed the potential ameliorating effect of zinc oxide resveratrol nanoparticles against Levofloxacin-induced liver damage in rats.

methodsFifty adult Wistar rats were split up into five groups at random. (n = 10). GI, (control): was orally gavaged with distilled water; G II (LFX): was orally given levofloxacin (LFX) (40 mg/kg BW). G III was orally administered zinc oxide resveratrol nanoparticles (Zn- RSV) (20 mg/kg BW). G IV: was given Zn-RSV as GIII and LFX as GII simultaneously (LFX + Zn-RSV). GV: was given LFX as GII and zinc oxide (20 mg/kg BW) (LFX + Zn). All treatments were given every other day for two months.

resultsAdministration of zinc oxide resveratrol nanoparticles (Zn-RSV NPs) significantly mitigated levofloxacin (LFX)-induced hepatotoxicity in rats. Compared to LFX-treated groups through improved liver function via lowered serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea, and creatinine levels. Also, reduced oxidative stress markers, decreased malondialdehyde (MDA) and nitric oxide (NO) levels in hepatic tissue and enhanced antioxidant defenses, increased superoxide dismutase (SOD) and catalase activities, restoring them to near-normal levels. Modulated apoptosis: Downregulated pro-apoptotic BAX expression and upregulated anti-apoptotic Bcl-2 expression, promoting cell survival. Zn-RSV NPs alleviated histopathological changes through mitigated LFX-induced degenerative and necrotic changes in hepatic tissue, preserving tissue architecture.

conclusionsThis study revealed that zinc oxide resveratrol nanoparticles modulated levofloxacin-induced hepatic damage by lowering inflammation and oxidative stress while increasing the activity of antioxidant enzymes in rat hepatic tissue.

Indexed as

Anti-Bacterial AgentsAntioxidantsChemical and Drug Induced Liver InjuryLevofloxacinNanoparticlesResveratrolZinc OxideAlanine TransaminaseAnimalsApoptosisAspartate AminotransferasesLiverMaleOxidative StressRatsRats, WistarAlanine TransaminaseAnti-Bacterial AgentsAntioxidantsAspartate AminotransferasesLevofloxacinResveratrolZinc OxideApoptosisLevofloxacinLiver injuryOxidative stressResveratrolZinc oxide nanoparticles

Identifiers

PMID41454399
PMCPMC12746628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.